Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6

References

• Argikar UA, Gomez J, Ung D, et al. (2010). Identification of novel metoclopramide metabolites in humans: in vitro and in vivo studies. Drug Metab Dispos 38:1295–307
   PubMed Web of Science ®Google Scholar
• Bateman DN, Craft AW, Nicholson E, Pearson ADJ. (1983). Dystonic reactions and the pharmacokinetics of metoclopramide in children. Br J Clin Pharm 15:557–9
   PubMed Web of Science ®Google Scholar
• Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. (2003). Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289–93
   PubMed Web of Science ®Google Scholar
• Chauret N, Dobbs B, Lackman RL, et al. (2001). The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes. Drug Metab Dispos 29:1196–200
   PubMed Web of Science ®Google Scholar
• Desta Z, Wu GM, Morocho AM, Flockhart DA. (2002). The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 30:336–43
   PubMed Web of Science ®Google Scholar
• Dipalma JR. (1990). Metoclopramide: a dopamine receptor antagonist. Am Fam Physician 41:919–24
   PubMed Web of Science ®Google Scholar
• Dixon M. (1953). The determination of enzyme inhibitor constants. Biochemical J 55:170–1
   PubMed Web of Science ®Google Scholar
• Emsley P, Cowtan K. (2004). Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126–32
   PubMed Web of Science ®Google Scholar
• Evans DC, Watt AP, Nicoll-Griffith DA, Baille TA. (2004). Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3–16
   PubMed Web of Science ®Google Scholar
• Gillam EMJ, Guo Z, Martin MV, et al. (1995). Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization. Arch Biochem Biophys 319:540–50
   PubMed Web of Science ®Google Scholar
• Hanna IH, Kim MS, Guengerich FP. (2001). Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity. Arch Biochem Biophys 393:255–61
   PubMed Web of Science ®Google Scholar
• Heydari A, Yeo KR, Lennard MS, et al. (2004). Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos 32:1213–7
   PubMed Web of Science ®Google Scholar
• Hollenberg PF, Kent UM, Bumpus NN. (2008). Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol 21:189–205
   PubMed Web of Science ®Google Scholar
• Huey R, Morris GM, Olson AJ, Goodsell DS. (2007). A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28:1145–52
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Steenwyk RC, Smith EB, et al. (2004). Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]-4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction. Chem Res Toxicol 17:174–84
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Obach RS, Maurer TS. (2007). Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug--drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 8:407–47
   PubMed Web of Science ®Google Scholar
• Kulanthaivel P, Barbuch RJ, Davidson RS, et al. (2004). Selective reduction of N-oxides to amines: application to drug metabolism. Drug Metab Dispos 32:966–72
   PubMed Web of Science ®Google Scholar
• Livezey MR, Nagy LD, Diffenderfer LE, et al. (2012). Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators. Drug Metab Lett 6:7--14
   PubMedGoogle Scholar
• Morris GM, Goodsell DS, Halliday RS, et al. (1998). Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 19:1639–62
   Web of Science ®Google Scholar
• Nagy LD, Mocny CS, Diffenderfer LE, et al. (2011). Substituted imidazole of 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine inactivates cytochrome P450 2D6 by protein adduction. Drug Metab Dispos 39:974–83
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug--drug interactions. Drug Metab Dispos 35:246–55
   PubMed Web of Science ®Google Scholar
• Rowland P, Blaney FE, Smyth MG, et al. (2006). Crystal structure of human cytochrome P450 2D6. J Biol Chem 281:7614–22
   PubMed Web of Science ®Google Scholar
• Rydberg P, Gloriam DE, Olsen L. (2010). The SMARTCyp cytochrome P450 metabolism prediction server. Bioinformatics 26:2988–9
   PubMed Web of Science ®Google Scholar
• Rydberg P, Olsen L. (2012). Predicting drug metabolism by cytochrome P450 2C9: comparison with the 2D6 and 3A4 isoforms. ChemMedChem 7:1202–9
   PubMed Web of Science ®Google Scholar
• Seto Y, Guengerich FP. (1993). Partitioning between N-dealkylation and N-oxygenation in the oxidation of N,N-dialkylarylamines catalyzed by cytochrome P450 2B1. J Biol Chem 268:9986–97
   PubMed Web of Science ®Google Scholar
• Shahrokh K, Orendt A, Yost GS, Cheatham TE III. (2012). Quantum mechanically derived AMBER-compatible heme parameters for various states of the cytochrome P450 catalytic cycle. J Comput Chem 33:119–33
   PubMed Web of Science ®Google Scholar
• Silfeler I, Arica V, Arica S, Dogan M. (2012). Development of acute dystonia in three brothers due to metoclopramide. J Res Med Sci 17:308–9
   PubMed Web of Science ®Google Scholar
• Silverman RB. (1988). Mechanism-based enzyme inactivation: chemistry and enzymology. Boca Raton (FL): CRC Press
   Google Scholar
• Teng L, Bruce RB, Dunning LK. (1977). Metoclopramide metabolism and determination by high-pressure liquid chromatography. J Pharm Sci 66:1615–18
   PubMed Web of Science ®Google Scholar
• van der Padt A, Van Schaik RH, Sonneveld P. (2006). Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. Neth J Med 64:160–2
   PubMed Web of Science ®Google Scholar
• Wang A, Savas U, Hsu MH, et al. (2012). Crystal structure of human cytochrome P450 2D6 with prinomastat bound. J Biol Chem 287:10834–43
   PubMed Web of Science ®Google Scholar
• Yu J, Paine MJ, Marechal LJD, et al. (2006). In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide. Drug Metab Dispos 34:1386–92
   PubMed Web of Science ®Google Scholar
• Zaretzki J, Rydberg P, Bergeron C, et al. (2012). RS-Predictor models augmented with SMARTCyp reactivities: robust metabolic regioselectivity predictions for nine CYP isozymes. J Chem Inf Model 52:1637–59
   PubMed Web of Science ®Google Scholar